Scarica l'app Stockscreener
37.07
3.92%
1.40
Dopo l'orario di chiusura:
37.07
Precedente Chiudi:
$35.67
Aprire:
$35.67
Volume 24 ore:
290.89K
Relative Volume:
0.69
Capitalizzazione di mercato:
$4.53B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+5.97%
1M Prestazione:
+19.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$34.78
$37.98
Intervallo di 1 settimana:
$34.78
$37.98
Portata 52W:
$24.51
$37.98
Parabilis Medicines Inc Stock (PBLS) Company Profile
Nome
Parabilis Medicines Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare PBLS vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
37.07 | 4.58B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Parabilis Medicines Inc Borsa (PBLS) Ultime notizie
Top Parabilis Medicines (PBLS) Competitors 2026 - marketbeat.com
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - moomoo.com
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - moomoo.com
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha
PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus
Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat
Parabilis Medicines: Q2 Earnings Snapshot - AOL.com
Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - Kalkine
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria
PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com
Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates - TradingView
Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000 - marketscreener.com
Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
Parabilis Medicines (NASDAQ:PBLS) Reaches New 1-Year HighWhat's Next? - marketbeat.com
Parabilis Medicines Ord Shs (PBLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Parabilis Medicines, Inc.Common Stock (Nasdaq:PBLS) Stock Quote - The Chronicle-Journal
Alphabet Reports Share Stake In SpaceX, Fervo Energy And Parabilis Medicines - TradingView
Parabilis Medicines (PBLS) Institutional Ownership 2026 - marketbeat.com
FMR LLC reports 10.3M-share position in Parabilis Medicines Inc (PBLS) - Stock Titan
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Buy" by Analysts - marketbeat.com
PBLS|Parabilis Medicines Ord Shs|Price:31.820|Chg%:+0.540 - TradingKey
Alexis Borisy: Biotech Is Winning the Science and Losing the Story - finance.biggo.com
Parabilis Medicines, Inc. Revenue Breakdown – NASDAQ:PBLS - TradingView
Scribe secures $129M in a rare gene editing IPO - BioPharma Dive
Parabilis Medicines(PBLS.US) 10% Shareholder Buys US$6.92 Million in Common Stock - Moomoo
Form 4 Parabilis Medicines For: 22 July - Investing.com India
Form 4 Parabilis Medicines For: 22 July By Investing.com - Investing.com South Africa
Parabilis Medicines, Inc. (PBLS) Revenue (TTM) - Zacks Investment Research
RA Capital boosts stake in Parabilis Medicines (PBLS) with stock buys - Stock Titan
Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42 - Moomoo
With record listing prices, what the mid-year IPO market says about the current state of biopharma - The Pharma Letter
Primary Markets Group June 2026 U.S. IPO Update - Seeking Alpha
Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest - MarketBeat
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart - mexc.co
Parabilis Medicines, Inc.'s Quiet Period Set To Expire on July 20th (NASDAQ:PBLS) - MarketBeat
Teresa Jurgensen Net Worth (2026) - GuruFocus
Thomas Rodolpho Kotarakos Net Worth (2026) - GuruFocus
Helen Huei In Ho Net Worth (2026) - GuruFocus
Soleus Capital Management, L.p. Net Worth (2026) - GuruFocus
Soleus Pe Gp Iii, Llc Net Worth (2026) - GuruFocus
Soleus Gp, Llc Net Worth (2026) - GuruFocus
PBLS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Mohammed Fawzi Benzaghou Net Worth (2026) - GuruFocus
Parabilis Medicines Inc Azioni (PBLS) Dati Finanziari
Non sono disponibili dati finanziari per Parabilis Medicines Inc (PBLS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):